PALL CORPORATION
NYSE : PLL

PALL CORPORATION

October 05, 2005 13:04 ET

Breakthrough Technology from Pall Increases Platelet Availability and Safety

EAST HILLS, N.Y.--(CCNMatthews - Oct 5, 2005) -

Pall Corporation (NYSE: PLL) announced today FDA clearance to market the new Pall Acrodose™ PL System. This is the first whole blood derived platelet system for pre-storage pooling and testing of leukoreduced whole blood derived platelets resulting in a transfusion-ready product for the hospital. This unique product increases the availability of lifesaving platelets, enhances patient safety and is more cost-effective for the hospital.

"Adequate platelet availability in some communities can sometimes be a challenge," says Allan Ross, President of Pall Medical. "The Acrodose PL System provides an opportunity for blood centers and hospitals to increase the availability of bacterially tested, leukoreduced, and pooled whole blood derived platelets in a cost-effective manner."

Platelets are derived from donors in either a one-to-two hour procedure called apheresis or from standard whole blood collections. Apheresed platelets are limited by donor availability. They are also time consuming and capital intensive to obtain. Regardless of which collection process is used, bacterial contamination of platelets is the leading infectious cause of illness and death from a blood transfusion. Single donor platelets are tested for bacterial contamination using a sensitive culture detection method such as Pall's eBDS, enhanced bacterial system. Whole blood derived platelet units on the other hand are tested using less sensitive methods due to cost, product loss, and logistical constraints of testing several individual units to obtain a standard therapeutic dose. This has resulted in a disparity of test sensitivities as well as underutilization of a valuable blood resource.

The new Acrodose PL System enables blood centers to pool individual whole blood derived platelets prior to storage and conduct a single bacterial contamination test with its integrated Pall eBDS technology. Studies using the Pall eBDS System with pooled platelets resulted in greater than 99 percent detection of bacteria that can contaminate platelets. With the new Acrodose PL System, blood centers will be able to provide hospitals and transfusion services with Acrodose(SM) Platelets, a transfusion-ready therapeutic dose of platelets that is both leukoreduced and bacteria tested with a highly sensitive culture based method. In turn, hospitals can reduce their handling costs by eliminating the need for further processing and testing.

"This is a seminal advance in blood safety and availability because hospitals now have assurance of access to more platelets that are safer than currently available whole blood derived platelets," says Roslyn Yomtovian, MD, Professor, Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, Ohio.

There are approximately 2.1 million transfusions annually in the U.S alone. On average, platelets are outdated and thrown away in five days making access to this lifesaving blood product precarious and costly, and especially problematic in emergency situations.

About Pall Corporation

Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceutical, transfusion medicine, semiconductor, water purification, aerospace and broad industrial markets. Total revenues for fiscal 2005 were $1.9 billion. The Company headquarters are in East Hills, New York with extensive operations throughout the world. Visit Pall at http://www.pall.com/.

This release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current Company expectations and are subject to risks and uncertainties which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to: fluctuations in foreign currency exchange rates; regulatory approval and market acceptance of new technologies; changes in product mix and product pricing and in interest rates and cost of raw materials; the Company's success in enforcing its patents and protecting its proprietary products and manufacturing techniques and its ability to achieve the savings anticipated from its cost reduction initiatives; global and regional economic conditions and legislative, regulatory and political developments; and domestic and international competition in the Company's global markets. Additional information regarding these and other factors is available on the Web at www.pall.com and is included in the Company's reports filed with the U.S. Securities and Exchange Commission. Copies of such reports can be obtained, without charge, at www.sec.gov.

Management uses certain non-GAAP measurements to assess Pall's current and future financial performance. The non-GAAP measurements do not replace the presentation of Pall's GAAP financial results. These measurements provide supplemental information to assist management in analyzing Pall's financial position and results of operations. Pall has chosen to provide this information to facilitate meaningful comparisons of past, present and future operating results and as a means to emphasize the results of on-going operations.

Editor's Notes:

Photos and additional information on the new Acrodose™ PL System can be found on http://www.pall.com/corporate_38334.asp

Several studies on the value of pre-storage pooled platelets will be presented at the upcoming AABB annual meeting in Seattle, Washington at the Washington State Convention and Trade Center, October 16, 2005 starting at 2:15 pm:

-- Susan L. Wilkinson, EdD, Associate Director and Associate Professor Hoxworth Blood Center University of Cincinnati Medical Center

-- Laura Cooling, MD MS, Assistant Professor, Department of Pathology, Associate Medical Director, Transfusion Medicine, University of Michigan

-- Scott Murphy, MD, Medical Director, American Red Cross, Penn Jersey Division

MULTIMEDIA AVAILABLE:

http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4988616



Contact Information